Balance Sheet Components

9 Months Ended

Sep. 30, 2026

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Components

Balance Sheet Components

Allowance for Expected Credit Losses

The following is a roll-forward of the allowances for expected credit losses related to trade accounts receivable for the three and nine months ended September 30, 2026 and 2025:

	Three Months Ended September 30,
	2026		2025
	(in thousands)
Beginning balance	$	6,526	$	7,823
Provision for (reversal of) expected credit losses	(295)		626
Write-offs	—		(30)
Total	$	6,231	$	8,419

	Nine Months Ended September 30,
	2026		2025
	(in thousands)
Beginning balance	$	8,018	$	7,259
Provision for (reversal of) expected credit losses	(1,421)		1,232
Write-offs	(366)		(72)
Total	$	6,231	$	8,419

Property and Equipment, net

The Company’s property and equipment consists of the following:

	Useful Life	September 30, 2026		December 31, 2025
		(in thousands)
Machinery and equipment	3-5 years	$	244,683	$	170,591
Computer equipment	3 years	5,706		3,629
Purchased and capitalized software held for internal use	3 years	21,561		21,195
Leasehold improvements	Lesser of useful life or lease term	105,881		62,152
Construction-in-process		122,652		94,016
Other property and equipment		1,693		679
		502,176		352,262
Less: Accumulated depreciation and amortization		(148,222)		(111,078)
Total property and equipment, net		$	353,954	$	241,184

The Company’s long-lived assets are principally located in the United States.

The Company did not incur any impairment charges during the three or nine months ended September 30, 2026 or 2025. Depreciation expense for the three months ended September 30, 2026 and 2025 was $14.7 million and $9.3 million, respectively. Depreciation expense for the nine months ended September 30, 2026 and 2025 was $40.4 million and $26.4 million, respectively.

Other Accrued Liabilities

The Company’s other accrued liabilities consisted of the following:

	September 30, 2026		December 31, 2025
	(in thousands)
Legal, audit and consulting fees	$	32,605	$	56,077
Testing and laboratory materials from suppliers	16,891		12,353
Clinical trials and studies	29,815		14,467
Marketing and corporate affairs	33,116		20,215
Property and equipment purchases	27,367		11,270
Accrued charges for third-party testing	26,609		20,874
Operating lease liabilities, current portion	15,932		15,581
Accrued third-party service fees	10,805		9,758
Reserves for refunds to insurance carriers	9,843		9,507
Sales and income tax payable	7,663		8,365
Accrued shipping charges	3,574		3,419
Other accrued expenses	3,196		6,773
Total other accrued liabilities	$	217,416	$	188,659